Letter to the editor concerning 'Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies'

摘要

The objective of this letter is to make the readers aware of the difficulties we experienced when trying to reproduce the results by Li et al. "Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies". The manuscript concluded that measurement of serum levels of auto-antibodies directed against insulin-like growth factor binding protein-2 (IGFBP-2) could potentially be used as diagnostic biomarkers in early cancer detection in patients suffering from glioma or colorectal cancer. Despite the exciting findings and the potential of using circulating IGFBP-2 auto-antibodies as early cancer biomarkers, we question the specificity of the in-house ELISA developed for IGFBP-2 auto-antibody measurement.